Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · IEX Real-Time Price · USD
6.10
-0.21 (-3.33%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Fulcrum Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for FULC stock have an average target of 14.38, with a low estimate of 6.00 and a high estimate of 23. The average target predicts an increase of 135.74% from the current stock price of 6.10.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 20, 2024.
Analyst Ratings
The average analyst rating for FULC stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 3 | 3 | 3 |
Buy | 2 | 3 | 3 | 4 | 4 | 4 |
Hold | 4 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 8 | 6 | 6 | 8 | 8 | 8 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $23 | Buy | Initiates | $23 | +277.05% | May 20, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $17 | Strong Buy | Reiterates | $17 | +178.69% | May 14, 2024 |
Goldman Sachs | Goldman Sachs | Hold → Strong Buy Upgrades $6 → $15 | Hold → Strong Buy | Upgrades | $6 → $15 | +145.90% | May 14, 2024 |
Oppenheimer | Oppenheimer | Buy Maintains $16 → $14 | Buy | Maintains | $16 → $14 | +129.51% | May 14, 2024 |
Goldman Sachs | Goldman Sachs | Hold → Strong Buy Upgrades $15 | Hold → Strong Buy | Upgrades | $15 | +145.90% | May 13, 2024 |
Financial Forecast
Revenue This Year
44.19M
from 2.81M
Increased by 1,475.40%
Revenue Next Year
19.46M
from 44.19M
Decreased by -55.96%
EPS This Year
-1.31
from -1.59
EPS Next Year
-1.65
from -1.31
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 143.1M | 142.8M | 256.6M | 326.3M | 348.1M |
Avg | 44.2M | 19.5M | 86.8M | 196.7M | 285.6M |
Low | n/a | n/a | n/a | 105.0M | 217.9M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 5,000.2% | 223.1% | 1,218.7% | 275.8% | 77.0% |
Avg | 1,475.4% | -56.0% | 346.2% | 126.5% | 45.2% |
Low | - | - | - | 20.9% | 10.8% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -0.63 | 0.40 | 1.71 | 2.38 | 1.88 |
Avg | -1.31 | -1.65 | -1.23 | -0.13 | 0.91 |
Low | -1.84 | -2.79 | -3.63 | -2.64 | 0.38 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | - |
Avg | - | - | - | - | - |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.